



P07 43453 (18810-80645)

1633 \$  
#15  
6-4-02  
P.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**

JUN 04 2002

TECH CENTER 1600/2900

In re application of: *Black et al.*

Serial No. 09/491,500

Filed: January 26, 2000

For: **METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A  
MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR**

Examiner: Sorbello, E.

Art Unit: 1633

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D. C. 20231

|  |                     |
|--|---------------------|
| CERTIFICATE OF FIRST CLASS MAILING   |                     |
| I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FILED BY FIRST CLASS MAIL AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D. C. 20231, ON <u>May 23, 2002</u> |                     |
| BY   | <u>ANN WEISS</u>    |
|  | <u>May 23, 2002</u> |
| (DATE OF SIGNATURE)  |                     |

Dear Sir/Madam:

Applicants' attorney submits herewith the full text of literature of which he is aware, that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. The filing of this Supplemental Information Disclosure Statement is after the mailing of a first Office Action on the merits.

The information disclosed herein includes literature cited in the International Search Reports (ISRs) in the related PCT Application Nos. PCT/US01/02743 and PCT/US01/02742 (both ISRs were mailed April 26, 2002), and which literature was not already provided by Applicants in a previous Information Disclosure Statement.

05/31/2002 SSESHE1 00000038 501597 09491500

01 FC0826 180.00 CH

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 CFR 1.97(h)). Further, the filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner.

It is believed that this Supplemental Information Disclosure Statement is being filed after the mailing of a first office action on the merits. The Commissioner is hereby authorized to charge \$180.00, the fee required under 37 C.F.R. § 1.17(p), or any other fee required or credit overpayments under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 50-1597.

Respectfully submitted,

By: 

Nisan A. Steinberg, Ph.D.  
Reg. No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP  
555 West Fifth Street  
Los Angeles, California 90013-1010  
Ofc: 213/ 896-6665  
Fax: 213/ 896-6600